Dr. Mark Fendrick discusses how the Geisinger V-BID Program leads to savings by eliminating drug co-payments
A study published in the February 2016 issue of The American Journal of Managed Care investigated the potential cost-savings of a $0 prescription co-pay program for chronically ill employees of the Geisinger Health System (GHS). Approximately 200 anti-hypertensive, anti-diabetic, and anti-lipid medications were provided at zero cost-sharing to 2251 GHS employees as part of an employee health and wellness program. The program showed positive cost-savings and a positive 5-year return on investment.
